NCT03732820: A reported trial by AstraZeneca
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03732820 |
|---|---|
| Title | A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 31, 2018 |
| Completion date | July 30, 2021 |
| Required reporting date | July 30, 2022, midnight |
| Actual reporting date | July 29, 2022 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | None |